Clinical features of patients with sepsis-induced cholestatic jaundice and risk factors for death
雷雨,黎嘉嘉,刘蓉安,曾帆,李贵森,兰蕴平
DOI: https://doi.org/10.3969/j.issn.1001-5256.2020.05.023
2020-01-01
Abstract:ObjectiveTo investigate the clinical features of patients with sepsis-induced cholestatic jaundice and the risk factors for death. MethodsA retrospective analysis was performed for the clinical data of 139 patients with sepsis-induced cholestatic jaundice who were admitted to Surgical Intensive Care Unit, Critical Care Medicine Center, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, from August 2011 to August 2019, and the patients were divided into survival group with 62 patients and death group with 77 patients. Age, sex, Acute Physiology and Chronic Health Evaluation II (APACHEII) score, and infection sites were recorded; related laboratory data at five time points were recorded, including total bilirubin (TBil), direct bilirubin (DBil), indirect bilirubin (IBil), prothrombin time (PT), international normalized ratio (INR), aspartate aminotransferase (AST), alanine aminotransferase (ALT), white blood cell count (WBC), neutrophils (NEU), procalcitonin (PCT), and lactic acid (Lac); the peak values of TBil, DBil, and IBil were also recorded, as well as duration of use of vasoactive agent, duration of mechanical ventilation, number of times of artificial liver plasma exchange, length of stay in the intensive care unit (ICU), Child-Pugh class, and jaundice grade. The independent samples t-test was used for comparison of normally distributed continuous data with homogeneity of variance between groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data with heterogeneity of variance between groups; the chi-square test was used for comparison of categorical data between groups; a binary logistic regression analysis was used to investigate the risk factors for death. ResultsThe mortality rate of patients with sepsis-induced cholestatic jaundice was 55.4%. Compared with the death group, the survival group had significantly lower levels of TBil, DBil, and IBil on days 14, 21, and 28 and significantly lower peak values of TBil, DBil, and IBil (TBil: Z=-3.230, -8.197, and -9.281, t=-5.371, all P＜0.01; DBil: Z=-4.708, -8.633, -9.579, and -8.238, P＜0.01; IBil: Z=-2.402, -6522, -8.113, and -5.300, all P＜0.01). The survival group had a higher proportion of patients with moderate jaundice, while the death group had a higher proportion of patients with severe jaundice (χ2=57.633, P＜0.01). Compared with the death group, the survival group had significantly lower PT and INR at all time points (at diagnosis and on days 7, 14, 21, and 28) (PT: Z=-3.173, -3.467, -2.660, -2.261, and -3.120, all P＜0.05; INR: Z=-3.141, -2.754, -3.230, -2.560, and -3.229, all P＜0.05) and significantly lower levels of AST on days 7, 14, 21, and 28 (Z=-2.484, -3.200, -3.298, and -4.277, all P＜0.05) and ALT on days 14, 21, and 28 (Z=-2.635, -2.667, and -4.656, all P＜0.01). Compared with the death group, the survival group had significantly lower levels of WBC and NEU on days 7, 14, and 21 (WBC: Z=-3.229, -2.987, and -4.537, all P＜0.01; NEU: t=-3.332, Z=-3.107 and -4.485, all P＜0.01), as well as significantly lower PCT at diagnosis and on days 14, 21, and 28 (Z=-4.844, -2.215, -2.869, and -7.442, all P＜0.05) and Lac at all time points (at diagnosis and on days 7, 14, 21, and 28) (Z=-4.316, -2.913, -3.068, -8.578, and -9.341, all P＜0.01). Compared with the death group, the survival group had significantly shorter duration of use of vasoactive agent (Z=-6.421, P＜0.01), duration of mechanical ventilation (Z=-2.005, P＜0.05), duration of artificial liver (Z=-4.822, P＜0.01), and length of stay in the ICU (t=-3.005, P＜0.01). TBil (odds ratio ［OR］=0.959, 95% confidence interval ［CI］: 0.929-0.991, P＜0.05), DBil (OR=1.056, 95%CI: 1.009-1105, P＜0.05), IBil (OR=1.071, 95%CI: 1.006-1.140, P＜0.05), WBC on day 7 (OR=31.365, 95%CI: 2.878-41.761, P＜0.05), WBC on day 14 (OR=5.859, 95% CI: 1.073-31.999, P＜0.05), NEU on day 7 (OR=0.007, 95%CI: 0.003-0409, P＜0.05), NEU on day 14 (OR=0.132, 95%CI: 0.023-0.765, P＜0.05), PCT at diagnosis (OR=1.062, 95%CI: 1.017-1.110, P＜0.05), PCT on day 7 (OR=0.920, 95%CI: 0.855-0.990, P＜0.05), PCT on day 28 (OR=12.711, 95%CI: 3.532-45.745, P＜0.05), duration of use of vasoactive agent (OR=1.657, 95%CI: 1.337-2.053, P＜0.05), duration of mechanical ventilation (OR=0.783, 95%CI: 0.634-0.967, P＜0.05), and duration of artificial liver (OR=1.534, 95%CI: 1.065-2.208, P＜0.05) were independent risk factors for death in patients with sepsis-induced cholestatic jaundice. ConclusionPatients with sepsis-induced cholestatic jaundice have a high mortality rate. The survival group has significantly lower levels and peak values of bilirubin than the death group in the middle and late stages of the disease, and there is a higher proportion of patients with moderate jaundice in the survival group and a higher proportion of patients with severe jaundice in the death group. Compared with the death group, the survival group has significantly lower degree of coagulation disorder, levels of AST and ALT, infection indices WBC, NEU, and PCT, and perfusion index Lac. Compared with the death group, the survival group has significantly better duration of use of vasoactive agent, duration of artificial liver support, duration of mechanical ventilation, and length of stay in the ICU. Bilirubin levels, infection indices WBC, NEU, and PCT, vasoactive agent, duration of mechanical ventilation, and duration of artificial liver support are independent risk factors for death in patients with sepsis-induced cholestatic jaundice.